Posts found in:
Grantees

The Role of EGR in establishing a malignant epigenetic program of therapy resistance in CLL Modification of gene structure constitutes a fundamental way healthy cells are reprogrammed into leukemia and gain therapeutic resistance. We will uncover how modifications associated with aggressive disease and relapse are created by reengineering normal cells. This will further our knowledge […]

Role of Epstein-Barr virus RNAs in the Pathogenesis of Virus-associated Lymphoid Tumors Epstein-Barr virus (EBV) infections are associated with a number of types of human cancer, including Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin’s lymphoma. EBV carries a number of viral genes whose products are known to result in increased cell growth and/or decreased cell death, […]

Ex Vivo expansion of hematopoietic stem cells for cord blood and allogeneic transplantations The ability to grow blood stem cells (HSCs) in culture would greatly improve the patient outcome in transplantation, and make cord blood to be useful for adult applications. We have identified several new growth factors, and established a very potent cell culture […]

Study Energy Sensing Signaling in Leukemia Stem Cells and Leukemia Development

Modeling T-Cell A.L.L. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer that preferentially affects children and adolescents. The leukemia is commonly associated with specific genetic abnormalities. Dr. Aifantis’ research focuses on one particular gene, known as Notch1, which is found in more than half of T-ALL patients and which has been generally recognized […]

Reducing Relapse of Acute Myeloid Leukemia after Hematopoietic Cell Transplantation We are conducting two clinical trials with novel, minimally toxic conditioning regimens – combining treosulfan or clofarabine, instead of fludarabine, with hematopoietic cell transplantation (HCT). Our goal is to reduce the incidence of recurrent leukemia following HCT, thereby increasing the likelihood of long-term survival.

Nras signaling in hematopoietic stem cells and leukemic stem cells

Enhancer rewiring in drug resistant T-ALL and its therapeutic implications T-cell acute lymphoblastic leukemia (T-ALL) is a disease that affects children and young adults, for which outcome has remained poor, often due to rapid development of resistance to existing therapies. We propose to determine the epigenetic alterations responsible for drug resistance in T-ALL, and develop […]

The Role of BCL-6 Regulated Chemokine Expression in the Pathogenesis of B-Cell Lymphomas Non-Hodgkin’s lymphoma (NHL) is the most common form of lymphoid malignancy in the adult population. Despite the advent of new drugs and treatment regimens, only 50% of NHL patients are cured, calling for the need of better understanding of the pathogenesis of […]

Fish oil (n-3 fatty acids) and non-Hodgkin lymphoma A growing body of evidence suggests that inflammation is a key factor in the development of cancer including various types of lymphomas. Fish oil, rich in n-3 fatty acids (eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids), has anti-inflammatory activity through inhibition of cyclooygenase-2 (COX-2) activity and has the […]

Identification of genetic dependencies in leukemia stem cells Leukemia cells reside in the bone marrow and derive signals from the surrounding bone marrow cells that are important for their survival and growth.  We aim to identify molecules on the surface of leukemia cells that are required for interaction with the bone marrow.  Blocking these interactions […]